-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Migraine is a common disabling neurological disease, and the most difficult one is chronic migraine (CM).
prevention
Adults with CM were included in the study and were randomly assigned to receive IV Ictizumab 100 mg, Ictizumab 300 mg or placebo, administered on day 0 and week 12.
The results showed that among the treated participants (n = 1,072), the average number of MMDs in each group at baseline was ≈16.
Figure 1.
To sum up, the results of this study show that in the middle plexus of CM patients, from the 2nd day to the 12th week after intravenous administration, Icotinizumab 100 and 300 mg are related to the significant reduction of MMDs, the tolerance and Security is good.
Original source:
Richard B Lipton, Peter J Goadsby, et al.
ncbi.
nlm.
nih.
gov/32209650/" target="_blank" rel="noopener">Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2 in this message